Rize Oncology Inc.
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 558.80K | 572.40K | 470.40K | 501.60K | 551.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 589.00K | 750.20K | 658.50K | 694.60K | 747.20K |
| Operating Income | -589.00K | -750.20K | -658.50K | -694.60K | -747.20K |
| Income Before Tax | -550.90K | -696.90K | -595.80K | -628.20K | -688.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.55 | -0.70 | -0.60 | -0.63 | -0.69 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -550.90K | -696.90K | -595.80K | -628.20K | -688.30K |
| EBIT | -589.00K | -750.20K | -658.50K | -694.60K | -747.20K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 154.98M | 155.47M | 165.60M | 175.36M | 185.03M |
| Average Diluted Shares Outstanding | 154.98M | 155.47M | 165.60M | 175.36M | 185.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |